Thermo Fisher Scientific Inc (NYSE:TMO) VP Seth H. Hoogasian sold 4,140 shares of the company’s stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $177.80, for a total transaction of $736,092.00. Following the completion of the sale, the vice president now directly owns 25,518 shares of the company’s stock, valued at $4,537,100.40. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Shares of Thermo Fisher Scientific Inc (NYSE:TMO) traded down 1.27% on Wednesday, reaching $191.58. 394,899 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $178.63 and a 200-day moving average price of $169.74. Thermo Fisher Scientific Inc has a 12-month low of $139.07 and a 12-month high of $193.88. The company has a market cap of $74.74 billion, a PE ratio of 33.38 and a beta of 1.05.
Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, topping the Zacks’ consensus estimate of $2.27 by $0.03. The business had revenue of $5 billion during the quarter, compared to the consensus estimate of $4.92 billion. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.03 earnings per share. Equities research analysts anticipate that Thermo Fisher Scientific Inc will post $9.35 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be paid a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.31%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.45%.
TRADEMARK VIOLATION NOTICE: This article was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://stocknewstimes.com/2017/09/13/thermo-fisher-scientific-inc-tmo-vp-seth-h-hoogasian-sells-4140-shares.html.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in Thermo Fisher Scientific by 2.4% in the second quarter. Vanguard Group Inc. now owns 26,600,394 shares of the medical research company’s stock valued at $4,640,970,000 after buying an additional 629,093 shares during the last quarter. BlackRock Inc. lifted its stake in Thermo Fisher Scientific by 1.6% in the second quarter. BlackRock Inc. now owns 23,355,469 shares of the medical research company’s stock valued at $4,074,828,000 after buying an additional 366,584 shares during the last quarter. Capital Research Global Investors lifted its stake in Thermo Fisher Scientific by 29.8% in the second quarter. Capital Research Global Investors now owns 17,304,897 shares of the medical research company’s stock valued at $3,019,185,000 after buying an additional 3,973,136 shares during the last quarter. State Street Corp raised its stake in shares of Thermo Fisher Scientific by 1.0% during the first quarter. State Street Corp now owns 16,085,954 shares of the medical research company’s stock worth $2,470,802,000 after purchasing an additional 164,367 shares during the last quarter. Finally, Capital World Investors raised its stake in shares of Thermo Fisher Scientific by 6.1% during the second quarter. Capital World Investors now owns 11,759,734 shares of the medical research company’s stock worth $2,051,721,000 after purchasing an additional 671,637 shares during the last quarter. Institutional investors own 83.52% of the company’s stock.
A number of analysts recently commented on TMO shares. Cleveland Research upgraded shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research note on Thursday, July 20th. Cowen and Company reiterated a “buy” rating and issued a $200.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, September 1st. Bank of America Corporation reissued a “buy” rating and issued a $210.00 price target (up previously from $200.00) on shares of Thermo Fisher Scientific in a report on Friday, July 21st. Zacks Investment Research lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $175.00 price target on shares of Thermo Fisher Scientific in a report on Wednesday, May 17th. Two research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $193.19.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.